
Onselex Pharmaceuticals is committed to changing what is possible for cancer patients. Our lead program, ONX-1006, is a novel nanoparticle reformulation of paclitaxel designed to enable sustained treatment and profound tumor reduction, with no treatment-related adverse effects observed at the NOAEL. We exist to help patients maintain quality of life and continuity in normal daily living throughout treatment.
Onselex adheres to sound principles, acts with integrity, and never compromises its values.
Onselex pursues the highest standards with passion and dedication to improve patients’ lives and become a leading biopharmaceutical company.
Onselex respects individual differences and diversity, listens closely to patients’ needs, and strives to ease their suffering.
Onselex sets ambitious goals, embraces thoughtful risk-taking, and advances new possibilities through innovative ideas.